[go: up one dir, main page]

WO2015092810A3 - Forme amorphe d'idélalisib - Google Patents

Forme amorphe d'idélalisib Download PDF

Info

Publication number
WO2015092810A3
WO2015092810A3 PCT/IN2014/000724 IN2014000724W WO2015092810A3 WO 2015092810 A3 WO2015092810 A3 WO 2015092810A3 IN 2014000724 W IN2014000724 W IN 2014000724W WO 2015092810 A3 WO2015092810 A3 WO 2015092810A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous form
idelalisib
relates
processes
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000724
Other languages
English (en)
Other versions
WO2015092810A2 (fr
Inventor
Shriprakash Dhar DWIVEDI
Brij Khera
Kumar Kamlesh SINGH
Nikhil Amar SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of WO2015092810A2 publication Critical patent/WO2015092810A2/fr
Publication of WO2015092810A3 publication Critical patent/WO2015092810A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une forme amorphe d'idélalisib et des procédés pour la préparation de ladite forme amorphe. L'invention concerne également des compositions pharmaceutiques qui contiennent ladite forme amorphe d'idélalisib.
PCT/IN2014/000724 2013-11-20 2014-11-19 Forme amorphe d'idélalisib Ceased WO2015092810A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3641/MUM/2013 2013-11-20
IN3641MU2013 IN2013MU03641A (fr) 2013-11-20 2014-11-19

Publications (2)

Publication Number Publication Date
WO2015092810A2 WO2015092810A2 (fr) 2015-06-25
WO2015092810A3 true WO2015092810A3 (fr) 2015-08-13

Family

ID=52785145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000724 Ceased WO2015092810A2 (fr) 2013-11-20 2014-11-19 Forme amorphe d'idélalisib

Country Status (2)

Country Link
IN (1) IN2013MU03641A (fr)
WO (1) WO2015092810A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097314A1 (fr) * 2014-12-19 2016-06-23 Sandoz Ag Formes amorphes et cristallines d'idélalisib et procédé pour les produire
US20180064714A1 (en) * 2015-03-13 2018-03-08 Mylan Laboratories Ltd Process for the Preparation of Amorphous Idelalisib and its Premix
WO2016157136A1 (fr) 2015-04-02 2016-10-06 Mylan Laboratories Ltd Formes cristallines de l'idélalisib
CN108033961A (zh) 2015-04-15 2018-05-15 上海方楠生物科技有限公司 一种艾德力布的无定型物及其制备方法
WO2017137097A1 (fr) * 2016-02-12 2017-08-17 Synthon B.V. Composition pharmaceutique comprenant de l'idelalisib sous forme amorphe
WO2017175184A1 (fr) * 2016-04-07 2017-10-12 Laurus Labs Limited Procédé de préparation de la forme amorphe d'idélalisib
EP3272348A1 (fr) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Composition pharmaceutique comportant de l'idelalisib
WO2019178596A1 (fr) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (fr) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
WO2013134288A1 (fr) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (fr) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
WO2013134288A1 (fr) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one

Also Published As

Publication number Publication date
IN2013MU03641A (fr) 2015-07-31
WO2015092810A2 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2016011306A3 (fr) Modifications de terminal de polynucléotides
WO2015081257A3 (fr) Dérivés d'aminopyridine utilisés comme inhibiteurs de kinases de la famille tam
WO2015085318A3 (fr) Vaccins adaptatifs ciblés
WO2015092810A3 (fr) Forme amorphe d'idélalisib
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
EP2991658A4 (fr) Compositions antimicrobiennes et leurs procédés de fabrication
EP3021843A4 (fr) Composés anti-viraux, compositions pharmaceutiques et méthodes d'utilisation correspondantes
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
IL241175A0 (en) A pharmaceutical preparation for the treatment of fungal infections
WO2016009401A3 (fr) Préparation du phosphate de tédizolid
WO2015029074A3 (fr) Compositions d'eltrombopag
WO2016001885A3 (fr) Forme amorphe d'hémitartrate d'eliglustat
WO2013164839A3 (fr) Forme amorphe d'apixaban, son procédé de préparation et compositions de celle-ci
EP3003324A4 (fr) Compositions pharmaceutiques
IL243435A0 (en) Pharmaceutical preparations of pancreatin with high potency
EP3642415A4 (fr) Compositions de nanolignocellulose et leurs procédés de production
EP3288636A4 (fr) Compositions pour le traitement de l'epistaxis
HK1223300A1 (zh) 皮质类固醇组合物
WO2014133811A3 (fr) Composés dérivés de plantes salvinia invasives et leurs procédés d'utilisation
EP3016935A4 (fr) Procédé pour la préparation d'intermédiaire de dolutégravir
WO2016109361A3 (fr) Inhibiteurs 3-fluoro-benzonitriles de la 11-bêta-hydroxylase
WO2016063289A3 (fr) Compositions de comprimé pharmaceutique comprenant de la rifaximine
WO2015044434A3 (fr) Fluoro-9-méthyl-β-carboline
WO2014128728A3 (fr) Formes solides de cabazitaxel et leurs procédés de préparation
WO2015108945A3 (fr) Compositions et méthodes pour l'administration d'agents thérapeutiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14851422

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14851422

Country of ref document: EP

Kind code of ref document: A2